Kairos Pharma, LTD.
KAPA· NYSE
KAPAKairos Pharma, LTD.
Who holds Kairos Pharma, LTD., from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 309.8K | New | $118.9K | 0% | Sep 2, 2026 |
| Vanguard Capital Management LLC | 231.9K | ±0% | $89K | 0% | Aug 13, 2026 |
| Geode Capital Management, LLC | 78.9K | −29.1% | $30.3K | 0% | Aug 12, 2026 |
| Vanguard Fiduciary Trust Co | 63.9K | ±0% | $24.5K | 0% | Aug 13, 2026 |
| SevenBridge Financial Group, LLC | 44.3K | ±0% | $17.1K | 0.1% | Aug 12, 2026 |
| Aptus Capital Advisors, LLC | 44.3K | ±0% | $17K | 0.1% | Aug 12, 2026 |
| Jane Street Group, LLC | 33.7K | New | $12.9K | 0% | Aug 14, 2026 |
| Susquehanna International Group, LLP | 29.3K | New | $11.2K | 0% | Aug 14, 2026 |
| State Street Corp | 24.1K | ±0% | $9.2K | 0% | Sep 22, 2026 |
| XTX Topco Ltd | 14.9K | New | $5.7K | 0.1% | Aug 14, 2026 |
| UBS Group AG | 6.3K | New | $2.4K | 0% | Aug 13, 2026 |
| Tower Research Capital LLC (TRC) | 3.7K | −5.8% | $1.4K | 0% | Aug 11, 2026 |
| Barclays PLC | 723 | New | $277 | 0% | Aug 14, 2026 |
| Virtu Financial LLC | 82.1K | New | $31 | 0.1% | Aug 13, 2026 |
